CJC-1295 Research Guide — GHRH Analog for Growth Hormone Research

## Introduction

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), a 44-amino-acid neuropeptide produced in the hypothalamus that stimulates the release of growth hormone (GH) from the anterior pituitary gland. The CJC-1295 molecule corresponds to the first 29 amino acids of endogenous GHRH (GRF 1-29) with specific structural modifications that enhance its biochemical stability and receptor-binding affinity compared to the native hormone.

The variant without Drug Affinity Complex (DAC) is distinguished by its shorter half-life of approximately 30 minutes. While this may seem like a limitation, the “no DAC” formulation preserves the natural pulsatile pattern of growth hormone secretion—a characteristic that is widely considered important for maintaining physiological GH signaling, as chronic non-pulsatile GH elevation can lead to receptor desensitization and feedback dysregulation.

CJC-1295 (no DAC) has reached Phase 2 clinical trial status and is classified as “Very Popular” within the research peptide community. It is frequently studied in combination with ghrelin mimetics such as Ipamorelin, which act through a complementary pathway to potentiate GH release.

## Mechanism of Action

CJC-1295 acts as a potent agonist of the GHRH receptor (GHRHR), a G-protein-coupled receptor expressed on the surface of somatotroph cells in the anterior pituitary. Upon receptor activation, intracellular signaling cascades are initiated, most notably the cAMP/PKA pathway, which drives the transcription, synthesis, and secretion of growth hormone.

The modified GRF 1-29 sequence incorporates amino acid substitutions that confer resistance to enzymatic degradation by dipeptidyl peptidase IV (DPP-IV) and other proteolytic enzymes. This structural stabilization extends the peptide’s active window relative to native GHRH while maintaining the receptor interaction profile that triggers physiological, pulsatile GH release.

**Key signaling cascade:**

- GHRH receptor activation → Adenylate cyclase stimulation → cAMP elevation

- Protein kinase A (PKA) activation → CREB phosphorylation

- Pituitary-specific transcription factor Pit-1 activation → GH gene transcription

- Secretory vesicle mobilization → Pulsatile GH release into circulation

- Hepatic GH receptor activation → IGF-1 synthesis and release

The resulting elevation in circulating insulin-like growth factor 1 (IGF-1) mediates many of the downstream anabolic effects attributed to GH signaling, including increased protein synthesis, muscle growth, and bone density modulation.

## Research Applications

**Growth Hormone / IGF-1 Axis Research.** CJC-1295 is primarily used as a research tool for studying the regulation of the GH/IGF-1 axis. Its ability to stimulate endogenous GH release provides a model for understanding pituitary function, feedback regulation, and the downstream metabolic effects of GH signaling.

**Muscle and Metabolic Research.** Preclinical studies using GHRH analogs like CJC-1295 have shown increases in lean body mass, reduced adiposity, and improved nitrogen retention in animal models.

**Bone Density Research.** GH and IGF-1 are known regulators of bone metabolism. Research with GHRH analogs has explored their potential to stimulate osteoblast activity and increase bone mineral density in models of age-related bone loss.

**Combination Research with Ghrelin Mimetics.** CJC-1295 without DAC is frequently paired with Ipamorelin in research protocols. This synergistic combination targets both arms of GH regulation.

**Anti-Aging Research.** Given the decline in GH and IGF-1 with advancing age, GHRH analogs have been investigated in models of age-related physiological decline.

## Dosage & Administration

CJC-1295 (no DAC) is administered via subcutaneous (SubQ) injection. Due to its short half-life (~30 minutes), multiple daily doses are typically employed.

**Standard research protocols:**

- Dose range: 100–300 mcg per administration

- Frequency: 1–3 times daily

- Typical protocol duration: 8–12 weeks

- Category: Growth Hormone / IGF-1 Axis

## Reconstitution Guide

For reconstitution of a 5 mg vial:

1. Wipe the rubber stopper thoroughly with an alcohol swab.

2. Inject 1–2 mL of bacteriostatic water (BAC water) slowly along the inner wall of the vial to minimize foaming.

3. Swirl gently to dissolve. Do not shake or vortex.

4. Allow the solution to clarify before withdrawing the dose.

**Dosage math:** 5 mg / 2 mL = 2,500 mcg/mL. A 200 mcg dose equals 8 units on a U-100 insulin syringe. A 100 mcg dose equals 4 units.

**Storage:** Store lyophilized powder at 2–8°C before reconstitution. Reconstituted solution should be refrigerated at 2–8°C and used within 28 days. Protect from light at all times.

## Safety & Side Effects

CJC-1295 (no DAC) has demonstrated a favorable safety profile in preclinical and early clinical research. The short half-life of the no-DAC variant is considered advantageous from a safety perspective, as it allows rapid clearance and reduces the risk of sustained supraphysiological GH elevation.

## References

This research guide draws on data compiled from peptidewiki.co. CJC-1295 and related GHRH analogs can be explored in depth via PubMed using the search terms “CJC-1295,” “GRF 1-29,” or “GHRH analog.”